A Phase 3 interventional study of TAK-771 in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Completed at 12 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 16th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to check how much TAK-771 stays in their blood over time, side effect from the study treatment or TAK-771, how much TAK-771 participants can receive without getting side effects from it, and if TAK-771 improves symptoms of primary immunodeficiency diseases (PID). This will help the study sponsor (Takeda) to work out the best dose to give people in the future.
The participants will be treated with TAK-771 for totally 27 or 30 weeks. Treatment period is consist of two periods called Epoch 1 and Epoch 2. In Epoch 1, different groups of participants will receive lower to higher doses of TAK-771 for 3 to 6 weeks. The study doctors will check for side effects from each dose of TAK-771. In Epoch 2, participants will receive TAK-771 once a 3 or 4 weeks until the end of 24 weeks.
There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 3, or 4 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Serum trough levels at screening/enrollment meet one of the following:
Exclusion Criteria
Abnormal laboratory values at screening/enrollment meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-771 included IGI 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI was increased from 1/3 of full dose to full dose in 3 weeks for participants who received TAK-771 once every 3 weeks, or from 1/4 of full dose to full dose in 6 weeks for participants who received TAK-771 once every 4 weeks.
Drug: TAK-771
TAK-771 included Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants received subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 27 for participants with 4-Week dosing interval or Week 25 for participants with 3-Week dosing interval.
Drug: TAK-771
Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Also known as: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771
The data was reported at Week 7, 11, 15, 19, 23, 27, and 31 for 4-Week interval and at Week 4, 7, 10, 13, 16, 19, 22, 25 and 28 for 3-Week interval.
Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Epoch 2: Maximum Concentration (Cmax) of Total Serum Levels of IgG and IgG Subclasses
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Time to Maximum Concentration (Tmax) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Area Under the Curve (AUC) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
AUC is expressed as grams\*day per liter/grams per kilograms \[(g\*day/L)/(g/kg)\].
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Half-life of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame: At multiple time points post-infusion from Week 7 for participants with 4-Week or Week 4 with 3-Week dosing interval up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval
Epoch 2: Apparent Total Clearance (CL/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Apparent Volume of Distribution (Vz/F) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Minimum Concentration (Cmin) of Total Serum Levels of IgG and IgG Subclasses (IgG1, IgG2, IgG3, and IgG4)
Time frame: Pre-infusion at Week 27 for participants with 4-Week or Week 25 with 3-Week dosing interval and post infusion at multiple time points up to Week 31 for participants with 4-Week dosing interval and up to Week 28 with 3-Week dosing interval.
Epoch 2: Serum Trough Levels of IgG Subclasses (IgG1, IgG2, IgG3, and IgG4) After Administration of TAK-771
Time frame: 4-Week dosing interval (Week 7, Week 11, Week 15, Week 19, Week 23, Week 27, and Week 31); 3-Week dosing interval (Week 4, week 7, Week 10, Week 16, Week 19, Week 22, Week 25, and Week 28)
Epoch 1 and 2: Trough Levels of Anti-Clostridium Tetani Toxoid Antibody After Administration of TAK-771
Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)
Epoch 1 and 2: Trough Levels of Anti-HBV Antibody After Administration of TAK-771
Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval)
Epoch 1 and 2: Trough Levels of Anti-HIB Antibody After Administration of TAK-771
Time frame: From Week 1, up to end of trial (EOS: Week 31 for participants with 4-Week dosing interval or Week 28 for participants with 3-Week dosing interval).
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs are defined as Adverse events (AEs) with onset after date-time of first dose of Investigational product (IP), or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With TAK-771-Related and TAK-771-Non-Related TEAEs
TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Serious and Non-serious TEAEs
TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Serious TEAE=any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: results in death, was life-threatening, requires inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI=investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable AESI.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Severe TEAEs
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Local and Systemic TEAEs
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With TEAEs Leading to Premature Discontinuation From Study
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Infusion-associated TEAEs
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Percentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Epoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160
Time frame: 4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)
Epoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH20
Time frame: 4-Week Dosing Interval (Week 7, Week 19, and Week 31); 3-Week Dosing Interval (Week 4, Week 16, and Week 28)
Percentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-771
Tolerability events is defined as a case that the infusion rate is reduced, or that the infusion is interrupted or stopped, due to a TEAE related to TAK-771 infusion.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Epoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks)
The number of weeks to reach final dose interval is defined as treatment duration of Epoch 1.
Time frame: Up to Week 4 for Participants with 4-Week Dosing Interval or Up to Week 3 for Participants with 3-Week Dosing Interval
Epoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks
Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Epoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks
Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Annual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year
The annual rate of validated ASBIs is calculated as the mean number of ASBIs per participant per year.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Annual Rate of All Infections Per Participant Per Year
The annual rate of all infections is calculated as the mean number of infections per participant per year.
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Healthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Healthcare Resource Utilization: Days on Antibiotics
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Healthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Healthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Healthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection
Time frame: From Week 1 up to Week 31 for Participants with 4-Week Dosing Interval or up to Week 28 for Participants with 3-Week Dosing Interval
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion
Total number of infusion sites injected in Epoch 2 / Total number of infusions administered in Epoch 2.
Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Infusion Parameters in Epoch 2: Number of Infusion Sites Per Month
Total number of infusion sites injected in Epoch 2 / (duration of Epoch 2 / 30.4375), where duration of Epoch 2 is calculated as the end date of the Epoch 2 - the start date of the Epoch 2 + 1.
Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Infusion Parameters in Epoch 2: Duration of Individual Infusions
End date and time of infusion in Epoch 2 - Start date and time of infusion in Epoch 2, for each infusion per participant.
Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Infusion Parameters in Epoch 2: Maximum Infusion Rate Per Site
Maximum Infusion Rate results from CRF / number of infusion sites/body.
Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Infusion Parameters in Epoch 2: Infusion Volume Per Site
Infusion Volume per Site is scheduled Dose results from CRF / number of infusion sites/body.
Time frame: From Week 7 up to Week 31 for Participants with 4-Week Dosing Interval or From Week 4 up to Week 28 for Participants with 3-Week Dosing Interval
Quality of Life (QOL): Pediatric Quality of Life Inventory (PEDS-QL)
The PEDS-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. In this study, 2-7 years (parent as observer), 8-13 years (participant as observer) for PEDS-QL health questionnaire will be analyzed. Higher scores indicate better quality of life (QOL) for all domains of the PEDS-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Four dimensions (physical, emotional, social, \& school functioning) are scored.
Time frame: 4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)
QOL: Short Form-36 Health Survey Version 2 (SF-36 v2)
The SF-36 is a generic quality-of-life instrument that has been widely used to assess Health-Related Quality of Life (HR QoL) of participants. In this study, 14 years and older (participant as observer) for SF-36 health questionnaire will be analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HR QoL. Physical component summary (PCS).
Time frame: 4-Week Dosing Interval (Week 1 and Week 31); 3-Week Dosing Interval (Week 1 and Week 28)
QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Index Score
The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. Participants select answer for each of the following 3-level dimensions: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression used to compute an index score ranging from 0 (worst imaginable health state) to 1 (best imaginable health state). An increase in the EQ-5D-3L index score indicates improvement.
Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
QOL: EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Health Questionnaire Visual Analogue Scale (VAS) Score
The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS), a vertical scale that allows the participants to indicate their health state that day, and ranges from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.
Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
Treatment Preference
Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin (IG) therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment.
Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Treatment Satisfaction: Questionnaire for Medication-9 (TSQM-9)
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
Time frame: 4-Week dosing interval (Week 1 and Week 31); 3-Week dosing interval (Week 1 and Week 28)
Participants with a confirmed diagnosis of primary immunodeficiency diseases (PID) took part in the study at 12 investigative sites in Japan from 24 January 2022 to 28 August 2023.
| Milestone | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Started | 16 | 0 |
| Pharmacokinetic analysis set 1 | 16 | 0 |
| Pharmacokinetic analysis set 2 | 0 | 0 |
| Completed | 16 | 0 |
| Not completed | 0 | 0 |
| Milestone | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Started | 0 | 16 |
| Pharmacokinetic analysis set 1 | 0 | 16 |
| Pharmacokinetic analysis set 2 | 0 | 4 |
| Completed | 0 | 16 |
| Not completed | 0 | 0 |
The data was reported at Week 7, 11, 15, 19, 23, 27, and 31 for 4-Week interval and at Week 4, 7, 10, 13, 16, 19, 22, 25 and 28 for 3-Week interval.
| grams/Liter (g/L) | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Week 7, 4-Week Interval | 9.372 ± 10.3 |
| Week 11, 4-Week Interval | 8.741 ± 13.7 |
| Week 15, 4-Week Interval | 8.929 ± 13.0 |
| Week 19, 4-Week Interval | 9.150 ± 15.5 |
| Week 23, 4-Week Interval | 8.944 ± 20.9 |
| Week 27, 4-Week Interval | 9.006 ± 18.4 |
| Week 31, 4-Week Interval | 9.159 ± 20.8 |
| Week 4, 3-Week Interval | 13.51 ± 29.7 |
| Week 7, 3-Week Interval | 13.15 ± 35.7 |
| Week 10, 3-Week Interval | 12.54 ± 43.2 |
| Week 16, 3-Week Interval | 13.50 ± 39.7 |
| Week 19, 3-Week Interval | 12.76 ± 46.9 |
| Week 22, 3-Week Interval | 12.79 ± 40.1 |
| Week 25, 3-Week Interval | 12.95 ± 57.6 |
| Week 28, 3-Week Interval | 12.70 ± 43.0 |
| g/L | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | 12.72 ± 23.4 |
| IgG Subclass (IgG 1) | 7.694 ± 16.7 |
| IgG Subclass (IgG 2) | 4.140 ± 23.0 |
| IgG Subclass (IgG 3) | 0.2396 ± 46.7 |
| IgG Subclass (IgG 4) | 0.3200 ± 36.3 |
| days | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | 6.94 (2.94 to 8.85) |
| IgG Subclass (IgG 1) | 3.92 (2.94 to 8.83) |
| IgG Subclass (IgG 2) | 3.92 (2.94 to 8.83) |
| IgG Subclass (IgG 3) | 2.99 (2.80 to 8.83) |
| IgG Subclass (IgG 4) | 3.88 (2.80 to 5.04) |
AUC is expressed as grams\*day per liter/grams per kilograms \[(g\*day/L)/(g/kg)\].
| (g*day/L)/(g/kg) | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG, AUCtau/Dose | 767.9 ± 40.0 |
| Total IgG, AUClast/Dose | 625.6 ± 55.2 |
| IgG Subclass (IgG 1), AUCtau/Dose | 432.4 ± 36.2 |
| IgG Subclass (IgG 1), AUClast/Dose | 370.7 ± 53.0 |
| IgG Subclass (IgG 2), AUCtau/Dose | 230.4 ± 25.2 |
| IgG Subclass (IgG 2), AUClast/Dose | 197.4 ± 40.5 |
| IgG Subclass (IgG 3), AUCtau/Dose | 7.916 ± 165.6 |
| IgG Subclass (IgG 3), AUClast/Dose | 5.449 ± 227.2 |
| IgG Subclass (IgG 4), AUCtau/Dose | 15.65 ± 37.1 |
| IgG Subclass (IgG 4), AUClast/Dose | 12.08 ± 53.4 |
| day | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | NA (NA to NA) |
| IgG Subclass (IgG 1) | 59.7 (40.4 to 77.9) |
| IgG Subclass (IgG 2) | 49.6 (40.8 to 71.4) |
| IgG Subclass (IgG 3) | NA (NA to NA) |
| IgG Subclass (IgG 4) | 35.9 (35.8 to 46.3) |
| milliliters per day (mL/day) | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | 76.84 ± 29.4 |
| IgG Subclass (IgG 1) | 117.0 ± 37.9 |
| IgG Subclass (IgG 2) | 219.6 ± 36.8 |
| IgG Subclass (IgG 3) | 6392 ± 176.6 |
| IgG Subclass (IgG 4) | 3234 ± 58.0 |
| mL | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | NA ± NA |
| IgG Subclass (IgG 1) | 8193 ± 54.9 |
| IgG Subclass (IgG 2) | 14650 ± 57.0 |
| IgG Subclass (IgG 3) | NA ± NA |
| IgG Subclass (IgG 4) | 165900 ± 88.3 |
| g/L | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Total IgG | 9.347 ± 17.9 |
| IgG Subclass (IgG 1) | 5.479 ± 10.7 |
| IgG Subclass (IgG 2) | 2.941 ± 19.8 |
| IgG Subclass (IgG 3) | NA ± NA |
| IgG Subclass (IgG 4) | 0.2255 ± 8.4 |
| g/L | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| IgG 1, Week 7, 4-Week Interval | 5.478 ± 12.1 |
| IgG 1, Week 11, 4-Week Interval | 5.106 ± 15.6 |
| IgG 1, Week 15, 4-Week Interval | 4.987 ± 11.9 |
| IgG 1, Week 19, 4-Week Interval | 5.063 ± 10.1 |
| IgG 1, Week 23, 4-Week Interval | 4.873 ± 10.8 |
| IgG 1, Week 27, 4-Week Interval | 5.066 ± 16.6 |
| IgG 1, Week 31, 4-Week Interval | 5.104 ± 14.0 |
| IgG 2, Week 7, 4-Week Interval | 3.147 ± 20.1 |
| IgG 2, Week 11, 4-Week Interval | 2.931 ± 15.0 |
| IgG 2, Week 15, 4-Week Interval | 2.912 ± 13.5 |
| IgG 2, Week 19, 4-Week Interval | 3.043 ± 16.5 |
| IgG 2, Week 23, 4-Week Interval | 2.976 ± 16.7 |
| IgG 2, Week 27, 4-Week Interval | 3.078 ± 15.5 |
| IgG 2, Week 31, 4-Week Interval | 3.091 ± 18.3 |
| IgG 3, Week 7, 4-Week Interval | 0.1380 ± NA |
| IgG 3, Week 11, 4-Week Interval | 0.1780 ± NA |
| IgG 3, Week 15, 4-Week Interval | 0.1390 ± NA |
| IgG 3, Week 27, 4-Week Interval | 0.2280 ± NA |
| IgG 4, Week 7, 4-Week Interval | 0.1933 ± 15.9 |
| IgG 4, Week 11, 4-Week Interval | 0.1965 ± 22.7 |
| IgG 4, Week 15, 4-Week Interval | 0.2020 ± 16.8 |
| IgG 4, Week 19, 4-Week Interval | 0.2057 ± 16.1 |
| IgG 4, Week 23, 4-Week Interval | 0.2054 ± 14.6 |
| IgG 4, Week 27, 4-Week Interval | 0.2228 ± 24.6 |
| IgG 4, Week 31, 4-Week Interval | 0.2265 ± 25.6 |
| IgG 1, Week 4, 3-Week Interval | 9.699 ± 55.6 |
| IgG 1, Week 7, 3-Week Interval | 8.906 ± 67.0 |
| IgG 1, Week 10, 3-Week Interval | 8.661 ± 66.7 |
| IgG 1, Week 16, 3-Week Interval | 8.860 ± 68.0 |
| IgG 1, Week 19, 3-Week Interval | 8.687 ± 68.9 |
| IgG 1, Week 22, 3-Week Interval | 8.641 ± 64.3 |
| IgG 1, Week 25, 3-Week Interval | 8.573 ± 82.9 |
| IgG 1, Week 28, 3-Week Interval | 8.845 ± 68.3 |
| IgG 2, Week 4, 3-Week Interval | 1.936 ± 105.6 |
| IgG 2, Week 7, 3-Week Interval | 1.859 ± 89.7 |
| IgG 2, Week 10, 3-Week Interval | 1.852 ± 83.0 |
| IgG 2, Week 16, 3-Week Interval | 1.964 ± 82.5 |
| IgG 2, Week 19, 3-Week Interval | 1.944 ± 82.1 |
| IgG 2, Week 22, 3-Week Interval | 1.957 ± 89.1 |
| IgG 2, Week 25, 3-Week Interval | 1.910 ± 73.5 |
| IgG 2, Week 28, 3-Week Interval | 1.948 ± 88.1 |
| IgG 4, Week 4, 3-Week Interval | 0.1680 ± NA |
| IgG 4, Week 7, 3-Week Interval | 0.1680 ± NA |
| IgG 4, Week 10, 3-Week Interval | 0.2010 ± NA |
| IgG 4, Week 16, 3-Week Interval | 0.2280 ± NA |
| IgG 4, Week 19, 3-Week Interval | 0.2120 ± NA |
| IgG 4, Week 22, 3-Week Interval | 0.2230 ± NA |
| IgG 4, Week 25, 3-Week Interval | 0.2060 ± NA |
| IgG 4, Week 28, 3-Week Interval | 0.2390 ± NA |
| IU/mL | Epoch 1 and 2 |
|---|---|
| Week 1 | 1.334 ± 84.4 |
| End of Trial (EOS) | 1.578 ± 68.4 |
| mIU/mL | Epoch 1 and 2 |
|---|---|
| Week 1 | 278.38 ± 125.0 |
| End of Trial (EOS) | 383.37 ± 57.7 |
| ug/mL | Epoch 1 and 2 |
|---|---|
| Week 1 | 1.958 ± 45.7 |
| End of Trial (EOS) | 1.519 ± 46.8 |
TEAEs are defined as Adverse events (AEs) with onset after date-time of first dose of Investigational product (IP), or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 81.3 | 93.8 |
TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP.
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| TEAE Related | 56.3 | 68.8 |
| TEAE Non-Related | 62.5 | 81.3 |
TEAEs are defined as AEs with onset after date-time of first dose of IP, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Serious TEAE=any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: results in death, was life-threatening, requires inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, important medical event. AESI=investigator-reported hypersensitivity reactions, events of disordered coagulation as bleeding/hypercoagulable AESI.
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Serious TEAEs | 6.3 | 6.3 |
| Non-serious TEAEs | 81.3 | 93.8 |
| Percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With Severe TEAEs | 0 | 6.3 |
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Local TEAEs | 43.8 | 43.8 |
| Systemic TEAEs | 75.0 | 87.5 |
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With TEAEs Leading to Premature Discontinuation From Study | 0 | 0 |
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With Infusion-associated TEAEs | 37.5 | 50.0 |
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Recorded as TEAEs | 0 | 0 |
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants With Clinically Significant Changes in Vital Signs and Body Weight Recorded as TEAEs | 0 | 0 |
| percentage of participants | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Epoch 2: Percentage of Participants Who Develop Anti-rHuPH20 Binding Antibody Titers of Greater Than or Equal to 1:160 | 0 |
| percentage of participants | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Epoch 2: Percentage of Participants Who Develop Neutralizing Antibodies to rHuPH20 | 0 |
Tolerability events is defined as a case that the infusion rate is reduced, or that the infusion is interrupted or stopped, due to a TEAE related to TAK-771 infusion.
| percentage of participants | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Percentage of Participants Who Experienced Tolerability Events Related to the Infusion of TAK-771 | 0 | 0 |
The number of weeks to reach final dose interval is defined as treatment duration of Epoch 1.
| weeks | Epoch 1: TAK-771 Ramp up Period |
|---|---|
| Epoch 1: Number of Weeks to Reach Final Dose Interval (3 Weeks or 4 Weeks) | 6.00 (3.0 to 6.9) |
| percentage of participants | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Epoch 2: Percentage of Participants Who Achieve a Treatment Interval of 3 or 4 Weeks | 100.0 |
| percenatge of participants | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Epoch 2: Percentage of Participants Who Maintain a Treatment Interval of 3 or 4 Weeks | 100.0 |
The annual rate of validated ASBIs is calculated as the mean number of ASBIs per participant per year.
| ASBIs per participant per year | Epoch 1 and 2 |
|---|---|
| Annual Rate of Validated Acute Serious Bacterial Infections (ASBIs) Per Participant Per Year | 0.00 ± 0.00 |
The annual rate of all infections is calculated as the mean number of infections per participant per year.
| infections per participant per year | Epoch 1 and 2 |
|---|---|
| Annual Rate of All Infections Per Participant Per Year | 2.69 ± 3.133 |
| number of days | Epoch 1 and 2 |
|---|---|
| Healthcare Resource Utilization: Days Not Able To Attend School/Work or To Perform Normal Daily Activities Due to Illness/Infection | 0 (0 to 26.8) |
| number of days | Epoch 1 and 2 |
|---|---|
| Healthcare Resource Utilization: Days on Antibiotics | 0 (0 to 40.2) |
| hospitalizations per year | Epoch 1 and 2 |
|---|---|
| Healthcare Resource Utilization: Number of Hospitalizations Due to Illness/Infection Per Year | 0.22 ± 0.591 |
| hospitalization days/participant/year | Epoch 1 and 2 |
|---|---|
| Healthcare Resource Utilization: Length of Stay in Days of Hospitalizations Due to Illness/Infection Per Participant Per Year | 0 (0 to 10.5) |
| Acute Physician Visits | Epoch 1 and 2 |
|---|---|
| Healthcare Resource Utilization: Number of Acute (Urgent or Unscheduled) Physician Visits Due to Illness/Infection | 1.74 (0 to 11.7) |
Total number of infusion sites injected in Epoch 2 / Total number of infusions administered in Epoch 2.
| infusion sites per infusion | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Infusion Parameters in Epoch 2: Number of Infusion Sites Per Infusion | 1.77 ± 0.394 |
Total number of infusion sites injected in Epoch 2 / (duration of Epoch 2 / 30.4375), where duration of Epoch 2 is calculated as the end date of the Epoch 2 - the start date of the Epoch 2 + 1.
| infusion sites per month | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Infusion Parameters in Epoch 2: Number of Infusion Sites Per Month | 2.02 ± 0.514 |
End date and time of infusion in Epoch 2 - Start date and time of infusion in Epoch 2, for each infusion per participant.
| minutes | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Infusion Parameters in Epoch 2: Duration of Individual Infusions | 74.0 (18 to 207) |
Maximum Infusion Rate results from CRF / number of infusion sites/body.
| mL/hour per site | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Infusion Parameters in Epoch 2: Maximum Infusion Rate Per Site | 222.3 ± 83.77 |
Infusion Volume per Site is scheduled Dose results from CRF / number of infusion sites/body.
| mL/site | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|
| Infusion Parameters in Epoch 2: Infusion Volume Per Site | 117.3 ± 77.73 |
The PEDS-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. In this study, 2-7 years (parent as observer), 8-13 years (participant as observer) for PEDS-QL health questionnaire will be analyzed. Higher scores indicate better quality of life (QOL) for all domains of the PEDS-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Four dimensions (physical, emotional, social, \& school functioning) are scored.
| score on a scale | Epoch 1 and 2 |
|---|---|
| Baseline (Week 1), 2-7 years, Total score, 4-week interval | 93.48 ± NA |
| Baseline (Week 1), 2-7 years, Total score, 3-week interval | 76.09 ± NA |
| Baseline (Week 1), 8-13 years, Total score, 4-week interval | 77.17 ± 18.091 |
| Change from Baseline (EOS/ET),2-7 years, Total score, 4-week interval | 2.17 ± NA |
| Change from Baseline (EOS/ET),2-7 years, Total score, 3-week interval | 11.96 ± NA |
| Change from Baseline (EOS/ET), 8-13 years, Total score, 4-week interval | 11.41 ± 3.843 |
The SF-36 is a generic quality-of-life instrument that has been widely used to assess Health-Related Quality of Life (HR QoL) of participants. In this study, 14 years and older (participant as observer) for SF-36 health questionnaire will be analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HR QoL. Physical component summary (PCS).
| score on a scale | Epoch 1 and 2 |
|---|---|
| Baseline (Week 1), 14 years and older, Physical component summary (PCS) score, 4-week interval | 51.85 ± 3.458 |
| Baseline (Week 1), 14 years and older, Physical component summary (PCS) score, 3-week interval | 53.30 ± 2.546 |
| Baseline (Week 1), 14 years and older, Mental component summary (MCS) score 4-week interval | 51.38 ± 14.060 |
| Baseline (Week 1), 14 years and older, Mental component summary (MCS) score 3-week interval | 59.90 ± 10.465 |
| Baseline (Week 1), >=14 years, Role/social component summary (RCS) score, 4-week interval | 49.67 ± 8.495 |
| Baseline (Week 1), >=14 years, Role/social component summary (RCS) score, 3-week interval | 53.50 ± 8.768 |
| Change from Baseline (EOS/ET), >=14 years, Physical component summary (PCS) score, 4-week interval | 0.20 ± 8.709 |
| Change from Baseline (EOS/ET), >=14 years, Physical component summary (PCS) score, 3-week interval | -1.85 ± 1.202 |
| Change from Baseline (EOS/ET), >=14 years, Mental component summary (MCS) score 4-week interval | -3.12 ± 5.605 |
| Change from Baseline (EOS/ET), >=14 years, Mental component summary (MCS) score 3-week interval | -3.55 ± 0.636 |
| Change from Baseline (EOS/ET), >=14 years, Role/social component summary (RCS) score 4-week interval | -0.80 ± 6.592 |
| Change from Baseline (EOS/ET), >=14 years, Role/social component summary (RCS) score,3-week interval | 4.90 ± 3.394 |
The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. Participants select answer for each of the following 3-level dimensions: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; 5) anxiety/depression used to compute an index score ranging from 0 (worst imaginable health state) to 1 (best imaginable health state). An increase in the EQ-5D-3L index score indicates improvement.
| score on a scale | Epoch 1 and 2 |
|---|---|
| Baseline (Week 1), 2-11 years, EQ-5D index score, 4-week interval | 1.0000 ± 0.00000 |
| Baseline (Week 1), 2-11 years, EQ-5D index score, 3-week interval | 0.6750 ± NA |
| Baseline (Week 1), 12 years and older, EQ-5D index score, 4-week interval | 0.9271 ± 0.12655 |
| Baseline (Week 1), 12 years and older, EQ-5D index score, 3-week interval | 1 ± 0 |
| Change from Baseline (EOS/ET), 2-11 years, EQ-5D index score, 4-week interval | 0.0000 ± NA |
| Change from Baseline (EOS/ET), 2-11 years, EQ-5D index score, 3-week interval | 0.3250 ± NA |
| Change from Baseline (EOS/ET), 12 years and older, EQ-5D index score, 4-week interval | 0.0729 ± 0.12655 |
| Change from Baseline (EOS/ET), 12 years and older, EQ-5D index score, 3-week interval | 0.0000 ± 0.00000 |
The EQ-5D-3L is a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS), a vertical scale that allows the participants to indicate their health state that day, and ranges from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.
| score on a scale | Epoch 1 and 2 |
|---|---|
| Baseline (Week 1), 2-11 years, EQ-5D VAS score, 4-week interval | 95.0 ± 7.07 |
| Baseline (Week 1), 2-11 years, EQ-5D VAS score, 3-week interval | 100.0 ± NA |
| Baseline (Week 1), 12 years and older, EQ-5D VAS score, 4-week interval | 76.3 ± 13.24 |
| Baseline (Week 1), 12 years and older, EQ-5D VAS score, 3-week interval | 85.0 ± 7.07 |
| Change from Baseline (EOS/ET), 2-11 years, EQ-5D VAS score, 4-week interval | -5.0 ± NA |
| Change from Baseline (EOS/ET), 2-11 years, EQ-5D VAS score, 3-week interval | -10 ± NA |
| Change from Baseline (EOS/ET), 12 years and older, EQ-5D VAS score, 4-week interval | 6.3 ± 9.78 |
| Change from Baseline (EOS/ET), 12 years and older, EQ-5D VAS score, 3-week interval | -2.5 ± 3.54 |
Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin (IG) therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment.
| Participants | Epoch 1 and 2 |
|---|---|
| 2-13 years, Before your participation in trial, where did you receive your IG therapy?=At hospital | 4 |
| 2-13 years, Before your participation in the trial, where did you receive your IG therapy?=At home | 2 |
| 2-13 years, Where do you prefer to receive your immunoglobulin therapy?=At hospital | 2 |
| 2-13 years, Where do you prefer to receive your IG therapy?=At home | 1 |
| 2-13 years, Where do you prefer to receive your IG therapy?=No Preference | 2 |
| 2-13 years, frequency of administration=Like very much | 3 |
| 2-13 years, frequency of administration=Like | 1 |
| 2-13 years, Frequency of administration=No Preference | 1 |
| 2-13 years, number of needlesticks per month=Like very much | 2 |
| 2-13 years, number of needlesticks per month=Like | 2 |
| 2-13 years, number of needlesticks per month=No preference | 1 |
| 2-13 years, total time spent for my treatment per month=Like | 3 |
| 2-13 years, total time spent for my treatment per month=No Preference | 2 |
| 2-13 years, ease of administration= Like | 1 |
| 2-13 years, ease of administration= No Preference | 3 |
| 2-13 years, The ease of administration= Dislike | 1 |
| 2-13 years, potential to self-administer=Like very much | 1 |
| 2-13 years, potential to self-administer=No preference | 2 |
| 2-13 years, potential to self-administer=Dislike | 1 |
| 2-13 years, potential to self-administer=Dislike very much | 1 |
| 2-13 years, ability to fit my treatment into my own schedule= Like | 3 |
| 2-13 years, ability to fit my treatment into my own schedule= No Preference | 2 |
| 2-13 years, overall convenience=Like | 4 |
| 2-13 years, overall convenience=No preference | 1 |
| 2-13 years, amount of time administration takes=Like | 2 |
| 2-13 years, amount of time administration takes=No preference | 2 |
| 2-13 years, amount of time administration takes=Dislike | 1 |
| 2-13 years, complexity of administration process=Like | 2 |
| 2-13 years, complexity of administration process=No preference | 2 |
| 2-13 years, complexity of administration process=Dislike | 1 |
| 2-13 years, My ability to self-administer without medical supervision=Like very much | 1 |
| 2-13 years, My ability to self-administer without medical supervision=No preference | 1 |
| 2-13 years, My ability to self-administer without medical supervision=Dislike | 1 |
| 2-13 years, My ability to self-administer without medical supervision=Dislike very much | 2 |
| 2-13 years, would you choose to continue receiving your treatment using IGg10% with rHuPH20 SC?=Yes | 5 |
| 14 years and older, Before your participation, where did you receive your IG therapy?=At hospital | 8 |
| 14 years and older, Before your participation, where did you receive your IG therapy?=At home | 7 |
| 14 years and older, Before your participation, where did you receive your IG therapy?=Other | 1 |
| 14 years and older, Where do you prefer to receive your IG therapy? = At hospital | 2 |
| 14 years and older, Where do you prefer to receive your IG therapy? = At home | 7 |
| 14 years and older, Where do you prefer to receive your IG therapy? = No preference | 2 |
| 14 years and older, frequency of administration=Like very much | 3 |
| 14 years and older, frequency of administration=Like | 7 |
| 14 years and older, frequency of administration=No preference | 1 |
| 14 years and older, number of needlesticks per month=Like | 8 |
| 14 years and older, number of needlesticks per month=No preference | 3 |
| 14 years and older, total time spent for my treatment per month = Like very much | 1 |
| 14 years and older, total time spent for my treatment per month=Like | 6 |
| 14 years and older, total time spent for my treatment per month=No preference | 2 |
| 14 years and older, total time spent for my treatment per month=Dislike | 2 |
| 14 years and older, ease of administration=Like | 2 |
| 14 years and older, ease of administration=No preference | 2 |
| 14 years and older, ease of administration=Dislike | 6 |
| 14 years and older, ease of administration=Dislike very much | 1 |
| 14 years and older, potential to self-administer=Like | 8 |
| 14 years and older, The potential to self-administer = No preference | 1 |
| 14 years and older, potential to self-administer=Dislike | 1 |
| 14 years and older, potential to self-administer=Dislike very much | 1 |
| 14 years and older, ability to fit my treatment into my own schedule= Like very much | 1 |
| 14 years and older, ability to fit my treatment into my own schedule= Like | 7 |
| 14 years and older, ability to fit my treatment into my own schedule= No preference | 2 |
| 14 years and older, ability to fit my treatment into my own schedule= Dislike | 1 |
| 14 years and older, overall convenience = Like | 8 |
| 14 years and older, overall convenience = No preference | 2 |
| 14 years and older, overall convenience = Dislike | 1 |
| 14 years and older, amount of time administration takes = Like | 7 |
| 14 years and older, amount of time administration takes = No preference | 3 |
| 14 years and older, amount of time administration takes = Dislike | 1 |
| 14 years and older, complexity of administration process=Like very much | 1 |
| 14 years and older, complexity of administration process=Like | 1 |
| 14 years and older, complexity of administration process=No preference | 2 |
| 14 years and older, complexity of administration process=Dislike | 6 |
| 14 years and older, complexity of administration process=Dislike very much | 1 |
| 14 years and older, My ability to self-administer without medical supervision=Like very much | 1 |
| 14 years and older, My ability to self-administer without medical supervision=Like | 6 |
| 14 years and older, My ability to self-administer without medical supervision = No preference | 1 |
| 14 years and older, My ability to self-administer without medical supervision = Dislike | 2 |
| 14 years and older, My ability to self-administer without medical supervision = Dislike very much | 1 |
| 14 years and older, choose to continue receiving your treatment using IGg 10% with rHuPH20 SC?=Yes | 9 |
| 14 years and older, choose to continue receiving your treatment using IGg 10% with rHuPH20 SC?= No | 2 |
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
| score on a scale | Epoch 1 and 2 |
|---|---|
| Baseline (Week 1), 2-12 years, Effectiveness, 4-week interval | 64.81 ± 3.208 |
| Baseline (Week 1), 2-12 years, Effectiveness, 3-week interval | 94.44 ± NA |
| Baseline (Week 1), 2-12 years, Convenience, 4-week interval | 44.44 ± 19.245 |
| Baseline (Week 1), 2-12 years, Convenience, 3-week interval | 38.89 ± NA |
| Baseline (Week 1), 2-12 years, Global satisfaction, 4-week interval | 59.52 ± 10.911 |
| Baseline (Week 1), 2-12 years, Global satisfaction, 3-week interval | 100.00 ± NA |
| Baseline (Week 1), 13 years and older, Effectiveness, 4-week interval | 64.81 ± 18.812 |
| Baseline (Week 1), 13 years and older, Effectiveness, 3-week interval | 63.89 ± 3.928 |
| Baseline (Week 1), 13 years and older, Convenience, 4-week interval | 62.04 ± 19.694 |
| Baseline (Week 1), 13 years and older, Convenience, 3-week interval | 44.44 ± 0.000 |
| Baseline (Week 1), 13 years and older, Global satisfaction, 4-week interval | 60.71 ± 8.748 |
| Baseline (Week 1), 13 years and older, Global satisfaction, 3-week interval | 64.29 ± 10.102 |
| Change from Baseline (EOS/ET), 2-12 years, Effectiveness, 4-week interval | 0.00 ± 0.000 |
| Change from Baseline (EOS/ET), 2-12 years, Effectiveness, 3-week interval | -27.78 ± NA |
| Change from Baseline (EOS/ET), 2-12 years, Convenience, 4-week interval | 13.89 ± 3.928 |
| Change from Baseline (EOS/ET), 2-12 years, Convenience, 3-week interval | 0.00 ± NA |
| Change from Baseline (EOS/ET), 2-12 years, Global satisfaction, 4-week interval | 10.71 ± 5.051 |
| Change from Baseline (EOS/ET), 2-12 years, Global satisfaction, 3-week interval | -28.57 ± NA |
| Change from Baseline (EOS/ET), 13 years and older, Effectiveness, 4-week interval | -12.04 ± 26.156 |
| Change from Baseline (EOS/ET), 13 years and older, Effectiveness, 3-week interval | 2.78 ± 3.928 |
| Change from Baseline (EOS/ET), 13 years and older, Convenience, 4-week interval | -3.70 ± 20.688 |
| Change from Baseline (EOS/ET), 13 years and older, Convenience, 3-week interval | 0.00 ± 7.857 |
| Change from Baseline (EOS/ET), 13 years and older, Global satisfaction, 4-week interval | -13.10 ± 26.885 |
| Change from Baseline (EOS/ET), 13 years and older, Global satisfaction, 3-week interval | -3.57 ± 5.051 |
Collected over From study start up to Week 28 for the 3-week dosing intervals and up to Week 31 for 4-week dosing intervals. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoch 1: TAK-771 Ramp up Period | 0/16 (0%) | 1/16 (6.3%) | 13/16 (81.3%) |
| Epoch 2: TAK-771 Full Dose Treatment Period | 0/16 (0%) | 1/16 (6.3%) | 15/16 (93.8%) |
| Event | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| Adrenal insufficiencyEndocrine disorders | 1/16 | 0/16 |
| GastroenteritisInfections and infestations | 1/16 | 0/16 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/16 | 1/16 |
| Event | Epoch 1: TAK-771 Ramp up Period | Epoch 2: TAK-771 Full Dose Treatment Period |
|---|---|---|
| PyrexiaGeneral disorders | 5/16 | 5/16 |
| NasopharyngitisInfections and infestations | 3/16 | 3/16 |
| COVID-19Infections and infestations | 0/16 | 2/16 |
| Chronic sinusitisInfections and infestations | 0/16 | 2/16 |
| HeadacheNervous system disorders | 2/16 | 1/16 |
| Infusion site erythemaGeneral disorders | 2/16 | 2/16 |
| Infusion site painGeneral disorders | 2/16 | 0/16 |
| Infusion site swellingGeneral disorders | 2/16 | 1/16 |
| Injection site erythemaGeneral disorders | 2/16 | 2/16 |
| Injection site painGeneral disorders | 2/16 | 2/16 |
Safety Analysis Set (SAS) included all enrolled subjects who received investigational drug at least once. Analyses of safety, tolerability and product administration were based on the SAS.
| Age, Continuous(Years) | Epoch 1: TAK-771 |
|---|---|
| Mean | 25.2 ± 16.86 |
| Sex: Female, Male(Participants) | Epoch 1: TAK-771 |
|---|---|
| Female | 6 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Epoch 1: TAK-771 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Epoch 1: TAK-771 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Epoch 1: TAK-771 |
|---|---|
| Japan | 16 |
| Height at Baseline(Centimeters (cm)) | Epoch 1: TAK-771 |
|---|---|
| Mean | 149.26 ± 25.892 |
| Weight at Baseline(Kilograms (kg)) | Epoch 1: TAK-771 |
|---|---|
| Mean | 44.33 ± 16.509 |
| Body Mass Index (BMI)(kilograms per meter square (kg/m^2)) | Epoch 1: TAK-771 |
|---|---|
| Mean | 19.05 ± 2.747 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2022 to primary completion in Aug 2023, 19 months.
Results were first posted in Nov 2024, 1 year 2 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Primary Immunodeficiency Diseases →